Statin Use Among Nursing Home Residents Varies Significantly

This article originally appeared here.
Share this content:
Statin Use Among Nursing Home Residents Varies Significantly
Statin Use Among Nursing Home Residents Varies Significantly

MONDAY, Aug. 14, 2017 (HealthDay News) -- Statin prescribing is considerable among nursing home residents, with significant variation in prescribing seen across physicians, according to a study published online Aug. 9 in the Journal of the American Geriatrics Society.

Michael A. Campitelli, M.P.H., from the Institute for Clinical Evaluative Sciences in Toronto, and colleagues conducted a population-based cross-sectional analysis involving 631 nursing home facilities to examine the variability of statin use among adults age 66 years and older residing in a nursing home facility.

The researchers found that 33.6 percent of the 76,226 nursing home residents assigned to 1,919 physicians were statin users. Among the 44,290 residents categorized as frail, 30.1 percent were statin users. Compared with non-frail residents, frail residents were significantly less likely to be statin users in an adjusted model (adjusted odds ratio, 0.62; 95 percent confidence interval, 0.58 to 0.65). Between-physician variability accounted for 9.1 percent of the residual unexplained variation in statin use (P < 0.001), after adjustment for resident characteristics. More low-outlying and high-outlying prescribers of statins were seen than expected by chance (17.4 and 12.0 percent, respectively) among the 894 physicians assigned 20 or more residents. High-outlying prescribing physicians had higher historical rates of statin prescribing.

"Further studies are required to evaluate the risks and benefits of statin use, and discontinuation, among nursing home residents to better inform clinical practice in this setting," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »